Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
400.43
+4.11 (1.04%)
At close: Nov 4, 2026, 4:00 PM EST
395.01
-5.42 (-1.35%)
Pre-market: Nov 5, 2026, 7:47 AM EST
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 19 analysts polled by S&P Global, Madrigal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $686.06. The average 1-year stock price forecast is 71.33% higher than the current stock price, while the lowest is $479 (+19.62%) and the highest is $962 (+140.24%).
Price Target: $686.06 (+71.33%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 12 | 13 | 15 | 15 | 15 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 17 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Maintains $709 → $743 | Buy | Maintains | $709 → $743 | +85.55% | Nov 4, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $685 | Buy | Reiterates | $685 | +71.07% | Nov 4, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $620 | Buy | Reiterates | $620 | +54.83% | Nov 4, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $612 → $633 | Buy | Reiterates | $612 → $633 | +58.08% | Nov 4, 2026 |
| Barclays | Barclays | Buy Maintains $962 | Buy | Maintains | $962 | +140.24% | Nov 4, 2026 |
Financial Forecast
Revenue This Year
1.59B
from 958.40M
Increased by 65.82%
Revenue Next Year
2.16B
from 1.59B
Increased by 35.68%
EPS This Year
-6.49
from -12.73
EPS Next Year
9.63
from -6.49
EPS and Forward PE are based on non-GAAP adjusted numbers.